THE BIO (더바이오)

Huons Co., Ltd. announced on November 5 that it has decided to acquire 2,647,378 shares of PanGen Biotech Inc. by investing KRW 14.3 billion. Huons will own PanGen shares through the acquisition of existing shareholders and a paid-in capital increase via third-party allocation. Huons also concluded a stock purchase agreement with CG Invites, the existing largest shareholder of PanGen, through a board of directors’ resolution. The company will also acquire new shares issued by PanGen. After the acquisition, Huons will own a total of 3,983,167 shares, representing a 31.53% stake to be PanGen’s largest shareholder. https://lnkd.in/gKX58kuB

Gencurix, a company specializing in cancer molecular diagnostics, announced on the 7th that it has signed a partnership agreement with Roche Diagnostics Korea, a subsidiary of global IVD leader Roche Diagnostics, to develop and commercialize cancer diagnostic kits using digital polymerase chain reaction (digital PCR) technology. https://lnkd.in/g3sij9ZS

HLB Innovation announced on November 5 that it has finalized its merger with Verismo Therapeutics, a Philadelphia-based developer of CAR-T treatments, and appointed Verismo founder Bryan Kim as the CEO of HLB Innovation. https://lnkd.in/gjeZ_zww

TiumBio announced on November 5 that it has filed a patent for its novel respiratory disease treatment, ‘NBX005’. The patent, titled ‘Anti-NE antibody and pharmaceutical composition for preventing or treating NE-hyperactivation related diseases comprising the same’, covers antibodies developed to address the hyperactivation of the ‘NE (Neutrophil Elastase) protein’, which is released from neutrophils in response to external stimuli such as infections or smoking. https://lnkd.in/gdF-Kn6m

Ildong Pharmaceutical announced on November 5 that its affiliates, including Yunovia and Idience, will participate in the 'BIO Europe 2024' event to showcase new drug candidates and pursue business opportunities. https://lnkd.in/gbY3upyn

Hugel’s 'Wellage' to join K-Beauty Boost in NYC 2024, aiming to accelerate global expansion https://lnkd.in/gKfZaqCz

Pfizer Korea announced on November 4 that its 20-valent pneumococcal conjugate vaccine, 'Prevenar 20', has received approval from the Ministry of Food and Drug Safety. Prevenar20 is a novel pneumococcal vaccine by Pfizer Korea, marking the first new release in approximately 14 years since 'Prevenar13', which was approved in Korea in 2010. Pfizer Korea highlights that this vaccine offers the broadest serotype coverage among protein conjugate vaccines approved in the country, adding seven new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) beyond those in Prevenar13. https://lnkd.in/gFQyASxV

AstraZeneca Korea reported on November 4 that it hosted the ‘AZ K-Bio Expressway Forum’ and pitching event in collaboration with the Korea Health Industry Development Institute (KHIDI). https://lnkd.in/gMj2MyRR

Y-Biologics, an antibody drug platform company, announced on November 4 that it will participate in ‘BIO Europe Fall 2024 (hereinafter referred to as BIO Europe)’ to engage in discussions about global technology transfer and strategic partnerships. Celebrating its 30th anniversary this year, BIO Europe is a global biotech partnering event organized by EBD Group, attracting around 2,800 companies from 60 countries to explore business opportunities and partnerships. This year’s event is taking place in Stockholm, Sweden, from November 4 to 6 (local time), under the theme ‘Promoting pharmaceutical development through collaboration and innovation.’ https://lnkd.in/gmsJegKc

Celltrion has launched its biosimilar treatment for autoimmune treatment, ‘Steqeyma®’ (ustekinumab), in the European market for the first time. With this addition to its product portfolio, Celltrion aims to further reinforce its position as a leading biopharmaceutical company. https://lnkd.in/gpQJS9G8